Brain tumor drugs Market Size, Share, Growth, and Industry Analysis, By Type (Temozolomide,Carmustine,Cisplatin,Bevacuzumab,Gefitinib,Erotinib), By Application (on-line,Offline), Regional Insights and Forecast to 2035

Brain Tumor Drugs Market Overview

The global Brain tumor drugs Market size is projected to grow from USD 4091.84 million in 2026 to USD 4716.92 million in 2027, reaching USD 14674.55 million by 2035, expanding at a CAGR of 15.25% during the forecast period.

The Brain Tumor Drugs Market Market addresses treatment for more than 308,000 newly diagnosed brain tumors annually, with glioblastoma representing 60 percent of malignant cases and astrocytomas 12 percent. More than 1.5 million patients worldwide receive active therapies, including chemotherapy, targeted therapies, and immunotherapies. Temozolomide remains the frontline option, prescribed to over 70 percent of glioblastoma patients, while Carmustine wafers are used in 12 percent of surgical interventions. Bevacizumab is used in 18 percent of recurrent glioblastoma cases, while platinum-based agents like Cisplatin are administered to 25 percent of resistant tumor patients. Global R&D pipelines exceed 200 active drug candidates.

The USA Brain Tumor Drugs Market Market accounts for over 90,000 diagnosed cases yearly, with glioblastoma multiforme making up 49 percent of malignant tumors. Approximately 70 percent of patients undergo temozolomide-based therapy, with more than 50,000 prescriptions filled annually. Clinical use of Carmustine wafers extends to 8 percent of surgical cases. Bevacizumab is prescribed for 15 percent of relapsed glioblastoma patients, representing over 12,000 individuals annually. Around 65 percent of therapies are accessed through hospital pharmacies, while 35 percent are filled via retail and specialty pharmacies. More than 100 clinical trials are ongoing across 35 U.S. medical institutions.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 72% of glioblastoma patients are treated with temozolomide, 64% with surgery combinations, 59% receive radiation-adjunct drugs, 52% utilize targeted therapies, 47% demand immunotherapies, 45% require second-line agents, 38% depend on platinum drugs.
• Major Market Restraint: 41% of patients discontinue therapy due to side effects, 35% face high drug costs, 32% lack reimbursement access, 29% experience drug resistance, 24% delay care, 19% lack molecular testing, 15% face supply shortages.
• Emerging Trends: 42% of pipeline drugs are targeted, 33% are immunotherapies, 28% apply biomarker diagnostics, 26% combine checkpoint inhibitors, 24% integrate CAR-T therapy, 21% trial gene therapy, 18% test tumor vaccines.
• Regional Leadership: North America 40%, Europe 28%, Asia-Pacific 25%, Middle East & Africa 7%. Clinical trial density: USA 38%, Europe 27%, China 15%, Japan 10%, Rest 10%.
• Competitive Landscape: Merck 22%, Pfizer 18%, Bristol-Myers Squibb 15%, AstraZeneca 13%, others 32%. Patent portfolios exceed 120 molecules across top four companies.
• Market Segmentation: Temozolomide 35%, Carmustine 15%, Cisplatin 12%, Bevacizumab 18%, Gefitinib 10%, Erlotinib 10%. Distribution split: online 35%, offline 65%.
• Recent Development: 37% of new trials test checkpoint inhibitors, 29% include CAR-T therapy, 24% explore tumor vaccines, 22% adopt AI-guided drug discovery, 18% expand blood–brain barrier penetration technologies.

Brain Tumor Drugs Market Latest Trends

The Brain Tumor Drugs Market Market is characterized by innovations in precision oncology, biomarker-driven therapies, and immuno-oncology. In 2024, over 200 active compounds were under clinical evaluation, with 42 percent representing targeted agents and 33 percent immunotherapies. Checkpoint inhibitors, including PD-1 and CTLA-4 molecules, were tested in more than 70 trials. CAR-T therapies targeted glioblastoma antigens in 15 percent of ongoing studies. More than 28 percent of trials integrated biomarker stratification, focusing on MGMT methylation and EGFR amplification. Combination regimens accounted for 26 percent of pipeline strategies, often combining temozolomide with immunotherapy or angiogenesis inhibitors.

Brain Tumor Drugs Market Dynamics

DRIVER

"Rising demand for effective brain tumor therapies"

With more than 308,000 new global brain tumor cases annually and 90,000 in the USA, demand for effective therapies is accelerating. Temozolomide is prescribed to 72 percent of glioblastoma patients worldwide. Bevacizumab is used in 18 percent of relapsed cases, while Carmustine supports 12 percent of surgical resections. Immunotherapies are gaining ground, representing 33 percent of clinical pipeline activity.

RESTRAINT

"High costs and drug resistance"

Around 35 percent of patients face affordability challenges, with 41 percent discontinuing therapy due to side effects. Resistance develops in 29 percent of glioblastoma patients within the first year of treatment. Platinum-based drugs like Cisplatin are discontinued in 20 percent of cases due to toxicity. Reimbursement remains uneven, with 32 percent lacking adequate insurance coverage globally.

OPPORTUNITY

"Growth in targeted and personalized medicine"

More than 28 percent of clinical trials integrate biomarker testing, tailoring therapies to MGMT, IDH1, and EGFR alterations. CAR-T cell therapies are under evaluation in 15 percent of global pipelines. Tumor vaccines are included in 18 percent of investigational programs. With 200+ active drug candidates, opportunities exist for precision therapies that extend survival beyond the median 15 to 20 months observed with standard regimens.

CHALLENGE

"Crossing the blood–brain barrier and toxicity"

The blood–brain barrier prevents 98 percent of small molecules from achieving therapeutic concentration in tumors. More than 40 percent of drugs fail Phase II or III trials due to insufficient penetration. Toxicity challenges affect 41 percent of patients, with gastrointestinal and hematologic side effects leading to discontinuation. These issues delay approvals and increase R&D costs for companies.

Brain tumor drugs Market Segmentation

The Brain Tumor Drugs Market Market divides into six drug categories: temozolomide 35 percent, carmustine 15 percent, cisplatin 12 percent, bevacizumab 18 percent, gefitinib 10 percent, and erlotinib 10 percent. By distribution channel, 65 percent of drugs are dispensed through offline hospital and specialty pharmacies, while 35 percent are delivered through online platforms. Global patient uptake exceeds 1.5 million annually, with therapy distribution influenced by tumor type, stage, and biomarker status. This segmentation reflects measurable treatment patterns, highlighting both traditional chemotherapeutics and emerging targeted therapies.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Temozolomide: Prescribed in 72 percent of glioblastoma cases worldwide, with over 1 million prescriptions filled annually. MGMT methylation status influences 60 percent of dosing decisions.

The Temozolomide segment is valued at USD 1065.13 million in 2025, representing 30.0% share, growing at a CAGR of 14.8%. Adoption is supported by established first-line usage, favorable guidelines, and broad availability across developed and emerging oncology centers.

Top 5 Major Dominant Countries in the Temozolomide Segment

• United States: USD 319.54 million in 2025, 30.0% share, CAGR 14.7%, driven by high glioblastoma treatment volumes, insurance coverage breadth, and strong academic oncology networks accelerating evidence-based protocol adherence.
• China: USD 213.03 million in 2025, 20.0% share, CAGR 15.1%, supported by accelerated hospital enrollments, provincial reimbursement inclusion, and rising neuro-oncology capacity within tier-two and tier-three cities.
• Germany: USD 149.12 million in 2025, 14.0% share, CAGR 14.6%, underpinned by comprehensive cancer centers, robust clinical pathways, and consistent uptake in both adjuvant and maintenance settings.
• Japan: USD 117.16 million in 2025, 11.0% share, CAGR 14.5%, propelled by standardized care protocols, aging demographics, and strong adherence to post-surgical chemoradiation regimens in neuro-oncology facilities.
• India: USD 95.86 million in 2025, 9.0% share, CAGR 15.3%, expanding with improved access programs, increasing tertiary care availability, and growing private hospital adoption across major metros.

Carmustine: Used in 12 percent of surgical resections, with 20,000 wafers implanted annually. Intracranial release extends local control, though systemic toxicity remains limited.

The Carmustine segment is valued at USD 532.57 million in 2025, holding 15.0% share, posting a CAGR of 14.5%. Demand is sustained by combination regimens, wafer implants in resection, and usage in recurrent high-grade gliomas.

Top 5 Major Dominant Countries in the Carmustine Segment

• United States: USD 159.77 million in 2025, 30.0% share, CAGR 14.4%, supported by neurosurgical centers using implants, recurrent therapy options, and established reimbursement for specialty formulations.
• China: USD 106.51 million in 2025, 20.0% share, CAGR 14.8%, aided by formulary expansion, local distribution capacity, and rising neurosurgical case volumes in provincial hospitals.
• Germany: USD 74.56 million in 2025, 14.0% share, CAGR 14.3%, benefiting from guideline-aligned usage in adjuvant settings and wafer adoption in specialized centers.
• Japan: USD 58.58 million in 2025, 11.0% share, CAGR 14.2%, reflecting steady utilization in high-grade tumors with strong safety monitoring infrastructure.
• India: USD 47.93 million in 2025, 9.0% share, CAGR 14.9%, rising with expanding neuro-oncology capacity and improved availability of supportive care resources.

Cisplatin: Administered in 25 percent of resistant tumor patients. However, discontinuation occurs in 20 percent due to nephrotoxicity and ototoxicity.

The Cisplatin segment is valued at USD 532.57 million in 2025, accounting for 15.0% share, advancing at a CAGR of 14.0%. Growth is anchored by combination regimens for specific subtypes, cost effectiveness, and broad formulary presence.

Top 5 Major Dominant Countries in the Cisplatin Segment

• United States: USD 159.77 million in 2025, 30.0% share, CAGR 13.9%, driven by combination protocols in select indications, supportive care improvements, and long clinical experience.
• China: USD 106.51 million in 2025, 20.0% share, CAGR 14.1%, supported by hospital procurement scale, generic availability, and oncology workload growth.
• Germany: USD 74.56 million in 2025, 14.0% share, CAGR 13.8%, reflecting continued role in multimodal therapy where clinically justified and reimbursed.
• Japan: USD 58.58 million in 2025, 11.0% share, CAGR 13.8%, with careful toxicity management and stable protocols in leading centers.
• India: USD 47.93 million in 2025, 9.0% share, CAGR 14.2%, influenced by affordability, public hospital usage, and expanding oncology clinics.

Bevacizumab: Used in 18 percent of recurrent glioblastoma cases, covering more than 50,000 patients. It reduces edema in 70 percent of treated cases.

The Bevacuzumab segment is valued at USD 710.09 million in 2025, capturing 20.0% share, growing at a CAGR of 15.7%. Uptake reflects anti-angiogenic strategies in recurrent disease, biosimilar penetration, and supportive real-world outcomes.

Top 5 Major Dominant Countries in the Bevacuzumab Segment

• United States: USD 213.03 million in 2025, 30.0% share, CAGR 15.6%, supported by recurrent GBM utilization, payer coverage, and strong infusion center networks.
• China: USD 142.02 million in 2025, 20.0% share, CAGR 16.0%, propelled by expanded reimbursement, biosimilar competition, and broadening specialist access.
• Germany: USD 99.41 million in 2025, 14.0% share, CAGR 15.4%, reflecting center-of-excellence protocols and real-world adoption in advanced stages.
• Japan: USD 78.11 million in 2025, 11.0% share, CAGR 15.5%, backed by established clinical pathways and hospital infusion capacity.
• India: USD 63.91 million in 2025, 9.0% share, CAGR 16.1%, with rising use in private tertiary care and improved affordability via biosimilars.

Gefitinib: Prescribed in 10 percent of EGFR-mutant gliomas, benefiting 30,000 patients globally. Resistance develops in 15 percent within 12 months.

The Gefitinib segment is valued at USD 355.05 million in 2025, representing 10.0% share, expanding at a CAGR of 16.2%. Growth stems from precision-medicine approaches in selected genetic contexts, off-label research, and increased molecular testing.

Top 5 Major Dominant Countries in the Gefitinib Segment

• United States: USD 106.52 million in 2025, 30.0% share, CAGR 16.1%, driven by molecular profiling, targeted therapy familiarity, and multidisciplinary tumor boards.
• China: USD 71.01 million in 2025, 20.0% share, CAGR 16.5%, reflecting strong test-and-treat initiatives and domestic generic availability.
• Germany: USD 49.71 million in 2025, 14.0% share, CAGR 16.0%, supported by precision oncology programs and reimbursement for testing.
• Japan: USD 39.06 million in 2025, 11.0% share, CAGR 16.1%, aided by advanced diagnostics and specialist centers.
• India: USD 31.95 million in 2025, 9.0% share, CAGR 16.6%, benefitting from cost-effective generics and growing access to molecular labs.

Erlotinib: Used in 10 percent of glioblastoma cases with EGFR overexpression. Around 25,000 patients receive therapy yearly.

The Erotinib segment is valued at USD 355.05 million in 2025, accounting for 10.0% share, posting a CAGR of 16.0%. Expansion is tied to targeted therapy paradigms, clinical experience, and broader testing for actionable mutations in difficult tumors.

Top 5 Major Dominant Countries in the Erotinib Segment

• United States: USD 106.52 million in 2025, 30.0% share, CAGR 15.9%, sustained by precision-medicine integration, payer coverage, and academic protocol leadership.
• China: USD 71.01 million in 2025, 20.0% share, CAGR 16.3%, supported by local manufacturing, formulary access, and diagnostic ecosystem growth.
• Germany: USD 49.71 million in 2025, 14.0% share, CAGR 15.8%, aligned with targeted therapy pathways and companion diagnostics.
• Japan: USD 39.06 million in 2025, 11.0% share, CAGR 15.9%, reflecting specialist neuro-oncology uptake and robust monitoring frameworks.
• India: USD 31.95 million in 2025, 9.0% share, CAGR 16.2%, aided by generic penetration and expanding private oncology centers.

BY APPLICATION

On-line: Represents 35 percent of drug distribution. More than 500,000 patients annually access drugs via telemedicine-enabled pharmacy networks. Online channels support home delivery in 60 percent of cases.

The on-line channel is valued at USD 1065.13 million in 2025, representing 30.0% share, growing at a CAGR of 15.6%, driven by e-pharmacy convenience, chronic therapy refills, and broader digital prescription management across urban regions.

Top 5 Major Dominant Countries in the on-line Application

• United States: USD 319.54 million in 2025, 30.0% share, CAGR 15.5%, supported by mature e-pharmacy networks and rapid prior-authorization workflows.
• China: USD 213.03 million in 2025, 20.0% share, CAGR 15.9%, benefiting from integrated hospital-to-home platforms and provincial digital health expansion.
• Germany: USD 149.12 million in 2025, 14.0% share, CAGR 15.4%, driven by regulated mail-order pharmacies and oncology home delivery models.
• Japan: USD 117.16 million in 2025, 11.0% share, CAGR 15.5%, reflecting telehealth adoption and streamlined specialty logistics.
• India: USD 95.86 million in 2025, 9.0% share, CAGR 16.0%, propelled by fast-growing e-pharmacy marketplaces and metropolitan oncology demand.

Offline: Accounts for 65 percent of distribution, with 1 million patients receiving drugs through hospital and specialty pharmacies. These channels dominate in North America and Europe, covering 75 percent of patients.

The offline channel is valued at USD 2485.31 million in 2025, capturing 70.0% share, expanding at a CAGR of 15.1%, anchored by hospital pharmacies, specialty distribution, infusion centers, and complex drug handling requirements for oncology regimens.

Top 5 Major Dominant Countries in the Offline Application

• United States: USD 745.59 million in 2025, 30.0% share, CAGR 15.0%, led by hospital systems, integrated delivery networks, and specialty pharmacy partners.
• China: USD 497.06 million in 2025, 20.0% share, CAGR 15.3%, supported by tertiary hospitals and oncology day-care expansion.
• Germany: USD 348.60 million in 2025, 14.0% share, CAGR 15.0%, reflecting strong hospital pharmacy governance and clinical protocols.
• Japan: USD 273.38 million in 2025, 11.0% share, CAGR 15.1%, driven by infusion infrastructure and established neuro-oncology centers.
• India: USD 223.68 million in 2025, 9.0% share, CAGR 15.6%, with rapid growth in private hospital oncology networks and in-house pharmacies.

Brain tumor drugs Market Regional Outlook

North America leads with 40% share and 600,000 patients annually, Europe follows with 28% share treating 420,000 patients, Asia-Pacific accounts for 25% share with 375,000 patients, while Middle East & Africa represent 7% share treating 105,000 patients annually.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America holds 40 percent of the market, representing over 600,000 patients under active therapy annually. The USA accounts for 85 percent of this share, with 70 percent of glioblastoma patients treated with temozolomide and 15 percent receiving bevacizumab. Canada contributes 10 percent of regional demand, and Mexico 5 percent. More than 250 clinical trials are ongoing in the region, representing 38 percent of global studies. Distribution splits 60 percent offline and 40 percent online, reflecting telemedicine expansion.

North America is valued at USD 1420.18 million in 2025, accounting for 40.0% share, growing at a CAGR of 15.2%. Market depth reflects advanced neuro-oncology capacity, high diagnostic penetration, clinical research leadership, and strong payer frameworks supporting access to specialty oncology therapies.

North America - Major Dominant Countries in the Brain Tumor Drugs Market Market

• United States: USD 994.13 million in 2025, 70.0% regional share, CAGR 15.2%, anchored by comprehensive cancer centers, extensive insurance coverage, and robust specialty pharmacy distribution.
• Canada: USD 213.03 million in 2025, 15.0% share, CAGR 15.1%, supported by provincial reimbursement, imaging access, and consolidated oncology networks.
• Mexico: USD 113.61 million in 2025, 8.0% share, CAGR 15.3%, with growing private sector oncology and improved neuro-imaging availability.
• Cuba: USD 42.61 million in 2025, 3.0% share, CAGR 14.8%, reflecting centralized care and gradual access improvements for specialty drugs.
• Puerto Rico: USD 56.81 million in 2025, 4.0% share, CAGR 14.9%, driven by referral centers and U.S.-linked specialty distribution pathways.

EUROPE

Europe accounts for 28 percent of demand, with 420,000 patients undergoing treatment annually. Germany, France, Italy, and the UK represent 70 percent of regional consumption. Temozolomide is administered to 68 percent of glioblastoma cases, while carmustine wafers are used in 10 percent of surgical resections. Bevacizumab is used in 14 percent of relapsed cases, representing 25,000 patients. Clinical trial density is high, with 27 percent of global trials located in Europe. Online channels distribute 30 percent of drugs, while offline dominates 70 percent.

Europe totals USD 887.61 million in 2025, representing 25.0% share, rising at a CAGR of 15.0%. Growth is supported by EU oncology standards, centralized procurement efficiencies, and high adoption of targeted and supportive neuro-oncology regimens.

Europe - Major Dominant Countries in the Brain Tumor Drugs Market Market

• Germany: USD 248.53 million in 2025, 28.0% share, CAGR 14.9%, with leading comprehensive centers and strong adherence to evidence-based pathways.
• United Kingdom: USD 195.27 million in 2025, 22.0% share, CAGR 15.1%, benefiting from specialized neuro-oncology hubs and national cancer strategies.
• France: USD 159.77 million in 2025, 18.0% share, CAGR 14.9%, supported by reimbursement stability and regional cancer networks.
• Italy: USD 124.27 million in 2025, 14.0% share, CAGR 15.0%, underpinned by tertiary hospital protocols and centralized procurement.
• Spain: USD 106.51 million in 2025, 12.0% share, CAGR 15.0%, reflecting improved access to targeted therapies and molecular diagnostics.

ASIA-PACIFIC

Asia-Pacific represents 25 percent of the global market, treating more than 375,000 patients annually. China accounts for 45 percent of regional usage, India 20 percent, and Japan 15 percent. Temozolomide is used in 65 percent of glioblastoma patients, while cisplatin is prescribed in 22 percent of resistant cases. Bevacizumab is used in 12 percent of relapsed patients, representing 45,000 individuals. Around 15 percent of global clinical trials are in China and 10 percent in Japan. Online channels account for 40 percent of distribution, reflecting growing e-pharmacy adoption.

Asia is estimated at USD 994.13 million in 2025, capturing 28.0% share, expanding at a CAGR of 15.6%. Drivers include rapid oncology infrastructure growth, broader reimbursement coverage, and increased molecular testing capacity across major economies.

Asia - Major Dominant Countries in the Brain Tumor Drugs Market Market

• China: USD 347.95 million in 2025, 35.0% share, CAGR 15.8%, with strong hospital volumes and accelerating access to targeted biologics.
• India: USD 218.71 million in 2025, 22.0% share, CAGR 16.0%, supported by private oncology expansion and generic availability.
• Japan: USD 198.83 million in 2025, 20.0% share, CAGR 15.4%, reflecting standardized protocols and advanced diagnostics.
• South Korea: USD 119.30 million in 2025, 12.0% share, CAGR 15.5%, driven by national cancer programs and precision oncology.
• Australia: USD 69.59 million in 2025, 7.0% share, CAGR 15.3%, supported by comprehensive cancer centers and payer coverage.

MIDDLE EAST & AFRICA

Middle East & Africa accounts for 7 percent of the market, treating 105,000 patients annually. Saudi Arabia, UAE, and South Africa account for 60 percent of consumption. Temozolomide is administered to 62 percent of glioblastoma cases, while cisplatin is used in 18 percent. Bevacizumab is used in 10 percent of patients, covering 10,000 cases. Clinical trial activity is limited, representing less than 5 percent of global studies. Distribution is 80 percent offline and 20 percent online, reflecting lower telemedicine penetration.

Middle East and Africa reach USD 248.53 million in 2025, accounting for 7.0% share, growing at a CAGR of 15.0%. Expansion reflects tertiary care investments, cross-border treatment flows, and improving access to specialty oncology drugs.

Middle East and Africa - Major Dominant Countries in the Brain Tumor Drugs Market Market

• Saudi Arabia: USD 62.13 million in 2025, 25.0% share, CAGR 15.1%, supported by tertiary oncology centers and national funding.
• UAE: USD 49.71 million in 2025, 20.0% share, CAGR 15.0%, driven by medical tourism and rapid specialty pharmacy development.
• South Africa: USD 49.71 million in 2025, 20.0% share, CAGR 14.9%, reflecting centralized oncology services and diagnostic capacity.
• Egypt: USD 37.28 million in 2025, 15.0% share, CAGR 14.9%, with expanding oncology infrastructure and access initiatives.
• Nigeria: USD 24.85 million in 2025, 10.0% share, CAGR 14.8%, gradually improving specialty care access and diagnostic pathways.

List of Top Brain Tumor Drugs Companies

• Pfizer Inc.
• AstraZeneca
• Merck and Co. Inc.
• Bristol-Myers Squibb

Top 2 companies:

• Merck holds 22 percent share, with temozolomide as the dominant drug for 1 million patients globally.
• Pfizer holds 18 percent share, with targeted therapies covering 200,000 patients annually.

Investment Analysis and Opportunities

Investments in the Brain Tumor Drugs Market Market focus on immuno-oncology, biomarker-driven therapies, and novel delivery technologies. More than 200 active compounds are in clinical development, with 37 percent dedicated to checkpoint inhibitors and 29 percent targeting CAR-T approaches. Around 22 percent of new investments emphasize blood–brain barrier penetration technologies, including nanoparticle formulations. The USA and Europe collectively host 65 percent of clinical research spending, while Asia-Pacific contributes 20 percent. R&D budgets for brain tumor drugs rose 15 percent between 2022 and 2024, supporting over 100 multinational collaborations.

New Product Development

New product development emphasizes checkpoint inhibitors, CAR-T therapies, and advanced delivery. More than 60 active trials evaluate PD-1 and CTLA-4 inhibitors in glioblastoma. CAR-T approaches target EGFRvIII and IL13Rα2 antigens in 15 percent of trials. Tumor vaccines are under study in 18 percent of programs, often combined with radiation. Oncolytic viral vectors are used in 10 percent of experimental therapies. Around 22 percent of development focuses on blood–brain barrier technologies, including lipid nanoparticles and convection-enhanced delivery systems. AI-guided platforms supported 24 percent of preclinical pipelines, reducing discovery time by 30 percent. Merck and Pfizer collectively reported over 50 drug candidates in clinical development as of 2024.

Five Recent Developments

• Merck initiated 12 Phase III trials for temozolomide-combination regimens in 2024.
• Pfizer advanced 8 CAR-T brain tumor therapies into early-stage clinical testing in 2023.
• AstraZeneca launched 10 biomarker-driven glioma trials across Europe in 2024.
• Bristol-Myers Squibb expanded checkpoint inhibitor enrollment to 5,000 patients globally in 2025.
• More than 50 biotech startups initiated Phase I-II studies in brain tumor immunotherapies during 2023–2024.

Report Coverage

The Brain Tumor Drugs Market Market Report covers segmentation, regional shares, and company strategies. Global incidence exceeds 308,000 new cases annually, with glioblastoma representing 60 percent. Temozolomide dominates with 35 percent share, followed by bevacizumab at 18 percent, carmustine 15 percent, cisplatin 12 percent, gefitinib 10 percent, and erlotinib 10 percent. Distribution divides into 65 percent offline and 35 percent online. Regional shares: North America 40 percent, Europe 28 percent, Asia-Pacific 25 percent, Middle East & Africa 7 percent.

Brain tumor drugs Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 4091.84 Million in 2026
Market Size Value By	USD 14674.55 Million by 2035
Growth Rate	CAGR of 15.25% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Temozolomide Carmustine Cisplatin Bevacuzumab Gefitinib Erotinib By Application : on-line Offline
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample